Wire
Nonprofit hospital drug prices face a new state review
The Massachusetts amendment would let regulators scrutinize how nonprofit hospitals set drug charges, including five years of increases and whether federally discounted 340B drugs are billed differently to patients and insurers.
Patients usually never see a hospital’s chargemaster, the internal price list behind many bills. In Massachusetts, that list could come under a new state review if lawmakers adopt the amendment now on the table. For nonprofit hospitals, the question would no longer be only what a drug costs, but why it costs that much.
The change adds a new section to Chapter 6D and gives the Health Policy Commission a way to review nonprofit hospital drug chargemaster pricing for a referred drug. The commission could act only after a referral from the Center for Health Information and Analysis under chapter 12C.
What hospitals would have to show
Once a referral lands, the commission could require the hospital to disclose the pricing details within a reasonable time on a standard reporting form. That includes the hospital’s chargemaster pricing methodology and any schedule of increases for the drug over the previous five calendar years.
Hospitals could also have to provide a written narrative, suitable for public release, explaining the factors behind the price. On top of that, the commission could ask for acquisition benchmarks, reimbursement benchmarks and any internal target margin or other pricing rationale tied to the drug. The aim is not just to see the number, but to understand the path that produced it.
The 340B question
The amendment pays special attention to 340B-acquired drugs, which are tied to a federal drug-discount program. Regulators could ask whether the hospital acquired, dispensed, replenished or accounted for the drug under 340B, and whether it used a different chargemaster price, markup formula, markup multiple, markup range or other pricing method for that drug than it used for the same or therapeutically comparable drugs.
That matters because pricing practices at nonprofit hospitals can ripple outward into patient bills and the broader cost of care, even when the bill itself is hidden from view. The new authority would not make a final finding of excessive pricing on its own, but it would give state regulators a clearer window into one of the least transparent parts of hospital billing.